ESMO Magnitude of Clinical Benefit Scale: Awareness and Utilisation Survey

The ESMO-MCBS was launched in May 2015 and was the first version of a validated and reproducible tool to assess the magnitude of clinical benefit from new cancer therapies.

ESMO is applying the scale in the grading of all new medications or indications of approved anti-neoplastic treatments in solid tumours by the European Medicines Agency since 2016. These grades are currently being presented in relevant ESMO Clinical Practice Guidelines or as an 'eUpdate', where we can rapidly inform of any changes and updates incorporating the ESMO-MCBS grade.

Aim

The objective of the survey was to understand the awareness of the ESMO-MCBS and how it is being used in supporting the work and decision-making process of various stakeholders.

Action

The survey is now closed and we take this opportunity to thank all who participated.

Presentation

The results from the survey were presented during the ESMO 2017, Madrid, Spain on Sunday 10 September 2017 at 16:30 ' Cost, value and assessment tools of therapies in modern oncology' - Alicante Auditorium.